Cancer Policy White House makes deal with Eli Lilly, Novo Nordisk to lower weight loss drug prices and begin Medicare coverage November 07, 2025Vol.51 No.41By Jacquelyn Cobb
Clinical Roundup Five-year monarchE outcome data demonstrate Verzenio’s long-term impact on cancer recurrence in high-risk early breast cancer October 27, 2023Vol.49 No.40
Drugs & Targets FDA broadens indication for Verzenio in HR+, HER2-, node-positive, high-risk early breast cancer March 10, 2023Vol.49 No.10
FDA, NCI align to simplify clinical research, producing a model “pragmatic” registration trial in NSCLC December 02, 2022Vol.48 No.43By Jacquelyn Cobb, Matthew Bin Han Ong and Paul Goldberg
Conversation with The Cancer Letter Roy Herbst: I hope Pragmatica-Lung will become the norm December 02, 2022Vol.48 No.43By Jacquelyn Cobb and Paul Goldberg
Conversation with The Cancer Letter Ellen Sigal: Pragmatica-Lung may be a model for other trials that are unnecessarily complex December 02, 2022Vol.48 No.43By Matthew Bin Han Ong
